CPV Partners’s MacroGenics MGNX Stock Holding History

CPV Partners’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,084,417	Closed	-$13.8M	–	2
2018 Q4	$13.8M	Buy	+1,084,417	New	+$18.2M	29.15%	2

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CPV Partners's MGNX Position: Q1 2019 in Review

CPV Partners sold out of MacroGenics (MGNX) in Q1 2019, closing a stake of 1,084,417 shares — an estimated $13.8M sold.

CPV Partners first reported a position in MGNX in Q4 2018 and held it in 1 quarter. The position peaked at $13.8M in Q4 2018. 157 funds tracked by Wall St. Rank hold MGNX as of Q1 2019.

CPV Partners reported no remaining MacroGenics position as of Q1 2019 after selling out during the quarter.
CPV Partners sold 1,084,417 MacroGenics shares in Q1 2019, an estimated $13.8M.
CPV Partners first reported a position in MacroGenics in Q4 2018 and held it in 1 quarter.
CPV Partners's MacroGenics position peaked at $13.8M in Q4 2018.
157 funds tracked by Wall St. Rank held MacroGenics as of Q1 2019.

Based on CPV Partners's 13F filing for Q1 2019, filed 15 May 2019.